In conclusion, 1.4 mg/m2 eribulin mesylate administered on days 1 and 8 of a 21-day cycle in combination with either weekly or tri-weekly trastuzumab was well tolerated in extensively pre-treated Japanese patients with advanced or recurrent HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.